ZEISS unveils next generation of ophthalmic laser VISULAS green at World Ophthalmology Congress
Barcelona/Spain | Carl Zeiss Meditec AG
VISULAS® green, the next generation of photocoagulation laser from ZEISS allows doctors to fully concentrate on the patient’s treatment procedure without interruption.
Today, the Medical Technology business group of ZEISS unveiled its next-generation VISULAS green® photocoagulation laser at the World Ophthalmology Congress in Barcelona. Retinal Photocoagulation Lasers are used to treat a variety of eye diseases including two major causes of blindness: Diabetic Retinopathy and Age-related Macular Degeneration. VISULAS green offers uninterrupted workflow by giving doctors the ability to monitor important treatment settings directly from the eyepiece and the ability to change these settings while operating the joystick, respectively.
"Not only is VISULAS green helping doctors treat retinal diseases and glaucoma, it’s also accelerating their daily clinical routine experience,” says Jim Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec. “With an uninterrupted workflow, doctors can work more efficiently and keep their focus on the patient.”
ZEISS VISULAS green offers a well-organized user interface enabling the doctor to focus on his patient entirely. The integrated data management provides user-specific treatment protocols and a contact lens database for multiple users.
Designed as a modular and expandable laser workstation, ZEISS VISULAS green is available in a classic and a comfort model and is equipped with a choice of single or dual fiber ports. The comfort model is upgradable to handle multi-spot photocoagulation with the ZEISS VITE option to reduce treatment times. VISULAS green displays the automated treatment parameter summary immediately after the procedure. The treatment summaries can be exported into ZEISS FORUM®, the company´s eye care data management system, to create a paperless laser treatment report.
“At ZEISS, we are committed to advance eye care by connecting the patient data every step of the way,” says Dr. Ludwin Monz, President, and CEO of Carl Zeiss Meditec. “Our comprehensive portfolio spans across screening, diagnostics, and treatment.”
In addition to VISULAS green, ZEISS will showcase its comprehensive portfolio at WOC Booth #4008, including HFATM3, CIRRUS® HD-OCT, Retina Workplace, Glaucoma Workplace, CLARUSTM 500, and Slit Lamp 220.
For more information, visit www.zeiss.com/visulasgreen
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.med@zeiss.com